← back to search

Pieter R. Cullis

University of British Columbia · CA
Area of research
Molecular Biology · Biomaterials
Research interest
Research interests include Lipid Membrane Structure and Behavior, RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques, and Nanoparticle-Based Drug Delivery.
h-index
109
citations
54,817
works
412
NIH funding
primary concept
email

Recent publications

NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
Frontiers in Science 2025cited by 14position: middledoi
Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the <scp>NCI</scp>'S Nanotechnology Characterization Laboratory Service to the Research Community
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 2025cited by 2position: middledoi
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Nature Reviews Drug Discovery 2024cited by 382position: firstdoi
Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions
Advanced Healthcare Materials 2024cited by 33position: middledoi
Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe <i>In Situ</i> Gene Editing in Human Skin
ACS Nano 2023cited by 33position: middledoi
Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective
Drug Delivery and Translational Research 2022cited by 50position: middledoi
The current landscape of nucleic acid therapeutics
Nature Nanotechnology 2021cited by 1,261position: middledoi
Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release
Small 2021cited by 64position: middledoi
PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease
Proceedings of the National Academy of Sciences 2021cited by 54position: middledoi
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Nature Nanotechnology 2019cited by 1,543position: lastdoi
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
Accounts of Chemical Research 2019cited by 491position: middledoi
On the role of helper lipids in lipid nanoparticle formulations of siRNA
Nanoscale 2019cited by 376position: lastdoi
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
Annals of Hematology 2019cited by 98position: middledoi
On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA
ACS Nano 2018cited by 606position: lastdoi
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
Nucleic Acid Therapeutics 2018cited by 538position: middledoi
Lipid Nanoparticle Systems for Enabling Gene Therapies
Molecular Therapy 2017cited by 1,094position: firstdoi
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
ACS Nano 2015cited by 195position: middledoi
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Molecular Therapy 2013cited by 613position: middledoi
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
Molecular Therapy — Nucleic Acids 2013cited by 474position: middledoi
Liposomal drug delivery systems: From concept to clinical applications
Advanced Drug Delivery Reviews 2012cited by 4,627position: lastdoi
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Angewandte Chemie International Edition 2012cited by 1,213position: middledoi
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Molecular Therapy — Nucleic Acids 2012cited by 658position: lastdoi
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core
The Journal of Physical Chemistry C 2012cited by 350position: lastdoi
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
Molecular Therapy — Nucleic Acids 2012cited by 135position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jayesh A. Kulkarni · FPInnovations7 papers (2018–2023)Dominik Witzigmann · FPInnovations6 papers (2019–2023)Roy van der Meel · Eindhoven University of Technology5 papers (2018–2021)Ying K. Tam · Acuitas Therapeutics (Canada)5 papers (2012–2024) · 5 papers (2012–2019)Sam Chen · University of Illinois Urbana-Champaign5 papers (2012–2021) · 3 papers (2012–2019)Jerry Leung · The University of Sydney3 papers (2019–2024)Martin A. Maier · University of Tübingen3 papers (2012–2019) · 3 papers (2012–2019)Muthiah Manoharan · Southwestern Medical Center3 papers (2012–2019)Yuen Yi C. Tam · Nanotherapeutics (United States)3 papers (2013–2019) · 3 papers (2012–2019) · 3 papers (2012–2019) · 3 papers (2012–2019) · 3 papers (2012–2019)Paulo J.C. Lin · Acuitas Therapeutics (Canada)3 papers (2012–2024)Sarah Hedtrich · University of British Columbia Hospital2 papers (2023–2024) · 2 papers (2012–2013)Carl L. Hansen · AbCellera (Canada)2 papers (2012–2012)